JP2006506441A5 - - Google Patents

Download PDF

Info

Publication number
JP2006506441A5
JP2006506441A5 JP2004553936A JP2004553936A JP2006506441A5 JP 2006506441 A5 JP2006506441 A5 JP 2006506441A5 JP 2004553936 A JP2004553936 A JP 2004553936A JP 2004553936 A JP2004553936 A JP 2004553936A JP 2006506441 A5 JP2006506441 A5 JP 2006506441A5
Authority
JP
Japan
Prior art keywords
polypeptide
box
hmgb
use according
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004553936A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006506441A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/036975 external-priority patent/WO2004046338A2/en
Publication of JP2006506441A publication Critical patent/JP2006506441A/ja
Publication of JP2006506441A5 publication Critical patent/JP2006506441A5/ja
Withdrawn legal-status Critical Current

Links

JP2004553936A 2002-11-20 2003-11-19 免疫応答を増大させるためのhmgbポリペプチドの使用 Withdrawn JP2006506441A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42784802P 2002-11-20 2002-11-20
PCT/US2003/036975 WO2004046338A2 (en) 2002-11-20 2003-11-19 Use of hmgb polypeptides for increasing immune responses

Publications (2)

Publication Number Publication Date
JP2006506441A JP2006506441A (ja) 2006-02-23
JP2006506441A5 true JP2006506441A5 (enExample) 2006-12-28

Family

ID=32326601

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004553936A Withdrawn JP2006506441A (ja) 2002-11-20 2003-11-19 免疫応答を増大させるためのhmgbポリペプチドの使用

Country Status (6)

Country Link
US (1) US20060121047A1 (enExample)
EP (1) EP1567544A4 (enExample)
JP (1) JP2006506441A (enExample)
AU (1) AU2003295653B2 (enExample)
CA (1) CA2505682A1 (enExample)
WO (1) WO2004046338A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
WO2005025604A2 (en) * 2003-09-10 2005-03-24 The General Hospital Corporation Use of hmgb and hmgb fragments to decrease specific immune response
CA2882022A1 (en) 2003-09-11 2005-03-24 Walter Newman Monoclonal antibodies against hmgb1
WO2006114805A2 (en) * 2005-04-28 2006-11-02 Fondazione Centro San Raffaele Del Monte Tabor Use of hmgb2 and hmgb3 proteins for medical applications
EP2105447A4 (en) * 2006-12-20 2010-05-05 Shino Test Corp ANTIBODIES OF AVIAN ORIGIN CAPABLE OF SPECIFICALLY BINDING TO HUMAN HMGB1, METHOD OF IMMUNOLOGICAL DETERMINATION FOR HUMAN HMGB1, AND IMMUNOLOGICAL DETERMINATION REAGENT FOR HUMAN HMGB1
US8470325B2 (en) 2007-02-15 2013-06-25 Kagoshima University Method of treating amykloidosis comprising administering an anti-HMGB-1 antibody
US8227417B2 (en) * 2008-07-25 2012-07-24 The United States Of America As Represented By The Secretary, Department Of Health And Human Services HMGN polypeptides as immune enhancers and HMGN antagonists as immune suppressants
HUE037157T2 (hu) 2010-01-21 2018-08-28 Univ Arkansas Vakcinavektorok, és eljárások immunválaszok fokozására
WO2011123396A1 (en) 2010-03-29 2011-10-06 University Of Southern California Compositions and methods for the removal of biofilms
KR102008120B1 (ko) 2010-06-09 2019-08-07 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 캄필로박터 감염을 감소시키기 위한 백신 및 방법
AU2011299025B2 (en) * 2010-09-09 2015-07-09 Nationwide Children's Hospital, Inc. Compositions and methods for the removal of biofilms
EA030929B1 (ru) 2013-02-14 2018-10-31 Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Арканзас КОМПОЗИЦИИ И СПОСОБЫ УСИЛЕНИЯ ИММУННЫХ ОТВЕТОВ НА Eimeria ИЛИ ОГРАНИЧЕНИЯ ИНФЕКЦИИ Eimeria
BR112015023024B1 (pt) 2013-03-15 2022-04-19 The Board Of Trustees Of The University Of Arkansas Vetor de vacina e composições farmacêuticas compreendendo o mesmo
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US9745366B2 (en) 2013-09-23 2017-08-29 University Of Southern California Compositions and methods for the prevention of microbial infections
US11248040B2 (en) 2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US10233234B2 (en) 2014-01-13 2019-03-19 Trellis Bioscience, Llc Binding moieties for biofilm remediation
JP6778681B2 (ja) * 2014-12-12 2020-11-04 ザ ファインスタイン インスティテュート フォー メディカル リサーチ Hmgb1媒介性炎症の治療
AU2016303688B2 (en) 2015-07-31 2023-06-15 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
CN108367049A (zh) 2015-12-11 2018-08-03 海德堡吕布莱希特-卡尔斯大学 Pkm2调节剂和hmgb1的组合制剂
TWI758288B (zh) 2016-05-03 2022-03-21 阿肯色州大學董事會 包含免疫刺激性及抗原性多肽的酵母菌疫苗載體以及其使用方法
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
US11746136B2 (en) 2017-03-15 2023-09-05 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
KR20210070331A (ko) 2018-10-05 2021-06-14 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 생물막 제거를 위한 hmgb1 단백질 유도체
WO2022243932A1 (en) * 2021-05-19 2022-11-24 Oxford University Innovation Limited Polypeptides related to hmgb1 useful for promoting tissue regeneration, compositions comprising same, and uses thereof
US20250101204A1 (en) * 2022-02-28 2025-03-27 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for protecting against cell damage and inflammation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
GB9217316D0 (en) * 1992-08-14 1992-09-30 Ludwig Inst Cancer Res Schwann cell mitogenic factor,its preparation and use
US6323329B1 (en) * 1995-12-21 2001-11-27 Jorn Bullerdiek Nucleic acid sequences of genes encoding high mobility group proteins
US6720472B2 (en) * 1996-07-12 2004-04-13 University Of Medicine And Dentistry Of New Jersey HMGI proteins in cancer and obesity
US6171779B1 (en) * 1996-07-12 2001-01-09 University Of Medicine & Dentistry Of New Jersey HMGI proteins in cancer
DE69737870T2 (de) * 1996-07-17 2008-02-07 Kaneka Corp. Medikamente für die diagnostik von autoimmunerkrankungen
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7151082B2 (en) * 1999-02-11 2006-12-19 The Feinstein Institute For Medical Research Antagonists of HMG1 for treating inflammatory conditions
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
WO2001070663A2 (en) * 2000-03-17 2001-09-27 Corixa Corporation Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
HUP0500042A3 (en) * 2001-05-15 2010-01-28 Long Island Jewish Res Inst Use of hmg fragments as anti-inflammatory agents
US7220723B2 (en) * 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US7304034B2 (en) * 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US20030014155A1 (en) * 2001-07-12 2003-01-16 Applied Material, Inc. High temperature substrate transfer robot

Similar Documents

Publication Publication Date Title
JP2006506441A5 (enExample)
Jahrsdörfer et al. CpG oligodeoxynucleotides as immunotherapy in cancer
KR101092043B1 (ko) 올리고뉴클레오티드 조성물 및 면역 반응 조절시 이의 용도
EP0855184A1 (en) Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
Tomai et al. TLR7/8 agonists as vaccine adjuvants
CA2412026A1 (en) Immunostimulatory rna/dna hybrid molecules
BRPI0010612B8 (pt) vacinas
ES3035198T3 (en) Cpg amphiphiles and uses thereof
Lingnau et al. Poly-L-arginine synergizes with oligodeoxynucleotides containing CpG-motifs (CpG-ODN) for enhanced and prolonged immune responses and prevents the CpG-ODN-induced systemic release of pro-inflammatory cytokines
Beignon et al. Immunization onto bare skin with synthetic peptides: immunomodulation with a CpG‐containing oligodeoxynucleotide and effective priming of influenza virus‐specific CD4+ T cells
JP2007508273A5 (enExample)
Xiang et al. Promising particle-based vaccines in cancer therapy
JP2002531521A5 (enExample)
CA2523032A1 (en) Vaccines for cancer therapy
JPH09511737A (ja) 免疫治療剤とその使用
Shi et al. Enhanced immune response to gastric cancer specific antigen Peptide by coencapsulation with CpG oligodeoxynucleotides in nanoemulsion
JP2003530088A5 (enExample)
JP2009544610A5 (enExample)
TWI705972B (zh) 惡性病變的組合治療
JP2006502228A5 (enExample)
AU2007266235A1 (en) Bioactive purified HspE7 compositions
Charoenvit et al. CEL-1000—a peptide with adjuvant activity for Th1 immune responses
Osorio et al. Immune responses to hepatitis B surface antigen following epidermal powder immunization
AU2005220156B2 (en) Peptides of IL1 beta and TNF alpha and method of treatment using same
WO2005084387A3 (en) Methods and compositions for hybrid cell vaccines for the treatment and prevention of cancer